<DOC>
	<DOCNO>NCT02899533</DOCNO>
	<brief_summary>In study positron emission tomography ( PET/CT ) image use evaluate evaluation estrogen receptor heterogeneity functionality Pulmonary Arterial Hypertension ( PAH ) use investigational radiotracer [ 18F ] fluoroestradiol ( FES ) .</brief_summary>
	<brief_title>18FFES PET/CT PAH</brief_title>
	<detailed_description>This feasibility study serial FES scan female patient Pulmonary Arterial Hypertension ( PAH ) determine whether patient detectable change FES SUV follow treatment fulvestrant separate therapeutic protocol IRB # 824861 `` Estrogen Receptor Antagonist Patients Pulmonary Arterial Hypertension ( ERA PAH ) '' . Subjects undergo 2 [ 18F ] FES PET/CT scan protocol . A baseline FES PET/CT occur Day 0 ( -2 day ) companion treatment trial prior initiation fulvestrant . The second FES PET/CT scan occur week 9 ( 63 ± 7 day ) initiation fulvestrant . We compare SUV value fulvestrant pre-treatment value .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>1 . Women postmenopausal , define one follow 1 . &gt; 50 year old ) menstruate precede 12 month per medical record review selfreport b ) folliclestimulating hormone level &gt; 40 IU/L screening OR 2 . &lt; 50 year folliclestimulating hormone level &gt; 40 IU/L screening OR 3. history bilateral oophorectomy per medical record review selfreport . 2 . Diagnosis Pulmonary Arterial Hypertension ( PAH ) per medical record review . 3 . Patients must candidate receive treatment companion therapeutic trial `` Estrogen Receptorα Inhibitor Patients Pulmonary Arterial Hypertension ( ERA PAH ) '' ( IRB # 824861 `` ERA PAH '' ) 4 . Participants must inform investigational nature study willing provide write informed consent participate study accordance institutional federal guideline prior studyspecific procedure . 1 . Inability tolerate image procedure opinion investigator treat physician 2 . Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study . 3 . Ineligible therapeutic trial IRB # 824861 `` ERA PAH '' entitle `` Estrogen Receptor Antagonist Patients Pulmonary Arterial Hypertension ( ERA PAH ) '' ( IRB # 824861 `` ERA PAH '' )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PAH</keyword>
	<keyword>Pulmonary hypertension</keyword>
</DOC>